ADVANCED GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Clinical trials for ADVANCED GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new ADVANCED GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for ADVANCED GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo attack on Hard-to-Treat cancers shows early promise
Disease control OngoingThis early-phase trial tests a combination of two drugs—trastuzumab deruxtecan (a targeted chemotherapy) and ceralasertib (which blocks a DNA repair enzyme)—in people with advanced solid tumors that have a HER2 mutation. The goal is to find the safest dose and see if the combo wo…
Matched conditions: ADVANCED GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 04:16 UTC
-
Virus-Enhanced treatment shows promise for Hard-to-Treat esophageal cancer
Disease control OngoingThis early-phase trial studies a new treatment for people with advanced esophageal or gastroesophageal cancer who cannot have surgery. It combines a cancer-killing virus (OBP-301) with standard chemotherapy and radiation. The main goal is to check safety and find the best dose, w…
Matched conditions: ADVANCED GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1 • Sponsor: NRG Oncology • Aim: Disease control
Last updated May 20, 2026 11:54 UTC